



Fig. S5. Western Blot. BTRT cells grown in 3D Matrigel culture were treated with vehicle, AMD3100 (10μM), trastuzumab (20 μg/ml), or their combination. A polypeptide that was designed as a CXCR4 antagonist but did not show biological function in the HER2+ breast cancer cells was used as a negative control (NC).